Global Psoriatic Arthritis Treatment Market

Global Psoriatic Arthritis Treatment Market Insights Forecasts to 2035

• The Global Psoriatic Arthritis Treatment Market Size Was valued at USD 11.45 Billion in 2024
• The Global Psoriatic Arthritis Treatment Market Size is Expected to Grow at a CAGR of around 9.12% from 2025 to 2035
• The Worldwide Psoriatic Arthritis Treatment Market Size is Expected to Reach USD 29.91 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

 

 

According to a research report published by Decisions Advisors and Consulting, the global psoriatic arthritis treatment market size was worth around USD 11.45 Billion in 2024 and is predicted to grow to around USD 29.91 Billion by 2035 with a compound annual growth rate (CAGR) of 9.12% from 2025 to 2035. The market is expected to grow because of new product launches because of the upcoming product pipeline because of the increasing consumer awareness and the rising number of diseases.

 

Market Overview

The global psoriatic arthritis treatment market refers to the worldwide industry focused on therapies used to manage psoriatic arthritis, which is a chronic autoimmune condition that causes joint inflammation and skin lesions. The market includes biologics and disease-modifying antirheumatic drugs (DMARDs) and NSAIDs and corticosteroids and new targeted therapies. The disease prevalence increase together with raised public awareness and better diagnostic tools create a market expansion driver. The development of biologic drugs together with new immunotherapy methods for targeted treatment creates better treatment results and improves patient health results. The market grows because emerging economies increase healthcare access and funding for autoimmune research advances. The market offers opportunities through personalized medicine development biosimilars that will lower treatment expenses digital health technology to enable remote monitoring and partnerships between pharmaceutical firms that will speed up new drug development and their worldwide market entry.

 

Report Coverage

This research report categorizes the psoriatic arthritis treatment market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the psoriatic arthritis treatment market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the psoriatic arthritis treatment market. 

 

Driving Factors

Obesity and overweight are medical conditions which result from excessive or irregular fat accumulation that threatens a person's health. In 2016, about 1.9 billion individuals aged 18 years and above were overweight. More than 650 million of those individuals were found to be obese. In 2016, 39% of people aged 18 and older had overweight status while 13% of adults showed obesity. In 2020, 39 million kids under five were overweight or obese. In 2016, approximately 340 million kids and adolescents aged 5 to 19 years were considered overweight or obese. The increasing prevalence of obesity will result in more cases of psoriatic arthritis according to the expected outcomes. The market expansion receives support from this development.

 

Restraining Factors

The market fails to grow because patients in developing regions face high treatment costs while facing multiple treatment barriers which include the adverse effects of long-term therapies and the need for regulatory approvals and their delayed diagnosis and the absence of disease knowledge.

 

Market Segmentation

The psoriatic arthritis treatment market share is classified into drug class and types.

• The biologics segment dominated the market in 2024, approximately 45% and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug class, the psoriatic arthritis treatment market is divided into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologics, and others. Among these, the biologics segment dominated the market in 2024, approximately 45% and is projected to grow at a substantial CAGR during the forecast period. The therapies demonstrate their therapeutic value through their ability to control inflammation and delay disease advancement in patients who have psoriatic arthritis. The therapies provide targeted immune pathway treatment which results in better symptom relief and enhanced life quality when compared to standard medications. The growth of this segment received support from increasing physician preference, strong clinical trial results, rising patient knowledge, and the expanding availability of advanced biologic treatments.

 

• The polyarticular segment accounted for the largest share in 2024, approximately 62% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the types, the psoriatic arthritis treatment market is divided into oligoarticular, polyarticular and others. Among these, the polyarticular segment accounted for the largest share in 2024, approximately 62% and is anticipated to grow at a significant CAGR during the forecast period. The condition requires treatment because it involves simultaneous joint damage which leads to more severe health problems and movement restrictions. Patients typically require long-term, intensive treatment, including biologics and combination therapies, which results in increased demand for their medical care. The segment achieved its dominant market share because of four factors which included higher diagnosis rates, greater disease burden, improved access to specialty care, and increased awareness about early management.

 

 

Regional Segment Analysis of the Psoriatic Arthritis Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the psoriatic arthritis treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the psoriatic arthritis treatment market over the predicted timeframe. The region's growth results from its advanced healthcare facilities and high healthcare spending per person and its substantial presence of top pharmaceutical companies. The U.S. market shares combine to create primary market dominance because of its extensive specialty care system and complete insurance benefits and its early implementation of biologics and new targeted therapies. The region experiences business growth because its strong regulatory system and reimbursement processes enable fast approval and market entry for new treatment innovations.

 

Asia-Pacific is expected to grow at a rapid CAGR in the psoriatic arthritis treatment market during the forecast period. The region's population growth together with heightened psoriatic arthritis awareness and diagnosis has created a need for both modern medical treatments and easily available healthcare services. The healthcare systems of China India and Japan are experiencing growth through increased funding better diagnostic facilities and expanded health insurance access which enables patients to receive treatment earlier and maintain their health condition.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the psoriatic arthritis treatment market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Pfizer, Inc.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

In June 2025, FDA approved Celltrion’s Steqeyma biosimilar (ustekinumab-stba) in a new 45mg/0.5mL single-dose vial for pediatric patients (ages 6-17, <60kg) with plaque psoriasis or psoriatic arthritis. Approval followed strong phase 3 data confirming comparable safety and efficacy.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the psoriatic arthritis treatment market based on the below-mentioned segments: 

 

Global Psoriatic Arthritis Treatment Market, By Drug Class 

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-modifying Antirheumatic Drugs (DMARDs)
• Biologics
• Others

 

Global Psoriatic Arthritis Treatment Market, By Types

• Oligoarticular
• Polyarticular
• Others

 

Global Psoriatic Arthritis Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the projected growth of the global psoriatic arthritis treatment market?

A: The market is expected to grow from USD 11.45 billion in 2024 to USD 29.91 billion by 2035, expanding at a CAGR of 9.12% due to innovation and rising disease prevalence.

 

2. Which drug class leads the psoriatic arthritis treatment market?

A: Biologics lead the market with about 45% share in 2024, driven by targeted immune action, superior clinical effectiveness, physician preference, and expanding approvals of advanced biologic therapies.

 

3. Why does the polyarticular segment dominate the market by type?

A: Polyarticular psoriatic arthritis affects multiple joints, causing severe symptoms and mobility limitations. Patients require long-term combination therapies, increasing treatment demand, diagnosis rates, and overall segment market share.

 

4. Why is North America the largest regional market?

A: North America leads due to advanced healthcare infrastructure, high healthcare expenditure, strong pharmaceutical presence, early biologics adoption, favorable reimbursement systems, and faster regulatory approvals supporting innovation.

 

5. Why is Asia-Pacific the fastest-growing region?

A: Asia-Pacific growth is driven by large population base, rising disease awareness, improving diagnostic capabilities, expanding healthcare infrastructure, better insurance coverage, and increasing government healthcare investments.